Geron (NASDAQ:GERN) Issues Earnings Results

Geron (NASDAQ:GERN) posted its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.04), Zacks reports. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%.

Geron Price Performance

Shares of GERN traded down $0.71 during midday trading on Wednesday, hitting $1.66. The company’s stock had a trading volume of 69,018,225 shares, compared to its average volume of 13,535,564. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.01 billion, a price-to-earnings ratio of -5.14 and a beta of 0.53. Geron has a one year low of $1.46 and a one year high of $5.34. The company’s fifty day simple moving average is $3.05 and its two-hundred day simple moving average is $3.83.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GERN. B. Riley decreased their target price on Geron from $5.50 to $3.50 and set a “buy” rating for the company in a research note on Tuesday, February 18th. Needham & Company LLC boosted their target price on Geron from $6.00 to $7.00 and gave the stock a “buy” rating in a report on Monday, January 13th. HC Wainwright lowered shares of Geron from a “buy” rating to a “neutral” rating in a research report on Wednesday. Finally, Barclays upgraded Geron to a “strong-buy” rating in a report on Friday, November 29th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Geron currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.91.

Geron Company Profile

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.